OraLiva awarded $1.9M National Institute of Dental and Craniofacial Research (NIDCR at NIH) Direct to Phase II SBIR grant for AI-linked cytomics-on-a-chip Read More
The People and Purpose Behind OraLiva
OraLiva was founded to help solve a long-standing challenge in oral health: detecting cancer early, during the routine dental visit, when outcomes are better and treatment is simpler.
Our team brings together expertise in diagnostics, cytology, AI, and clinical operations to make accurate, non-invasive cancer screening part of everyday care.
OraLiva was built on decades of research led by principal founder Dr. John T. McDevitt. His academic lab at NYU helped pioneer the use of single-cell analysis and microfluidic technologies for early disease detection.
OraLiva is advancing toward a regulated point-of-care diagnostic device, building on its current lab-developed platform. Our roadmap includes expanding clinical partnerships, deepening AI capabilities, and preparing for broader access across dental networks
See how OraLiva can improve outcomes, simplify workflow, and support earlier diagnosis, all from the chairside. Lets talk or book a demo.
Join OraLiva's Waitlist
